Clinical Trials: Page 8

  • A sign for Acadia Pharmaceuticals is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Acadia Pharmaceuticals
    Image attribution tooltip

    Acadia to scrap Prader-Willi drug after study setback

    The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential competitor to Soleno’s fast-selling Vykat. 

    By Kristin Jensen • Sept. 24, 2025
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers says next-gen blood cancer drug hits goal in key study

    The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.

    By • Sept. 23, 2025
  • An illustration of immune cells attacking a tumor. Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Oncology's research boom

    More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

    By BioPharma Dive staff
  • Friendly relationship between caregiver and happy eldery person during nursing at home.
    Image attribution tooltip

    Adobe Stock

    Image attribution tooltip
    Sponsored by EmVenio Clinical Research

    Meet the new EmVenio – where science meets people

    EmVenio makes clinical trial participation easier, more inclusive and more reflective of our world.

    By EmVenio Clinical Research • Sept. 22, 2025
  • Close-up on a scientist using a mobile app on a digital tablet while working at the laboratory
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roivant pill succeeds in rare inflammatory disease trial

    A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.

    By • Sept. 17, 2025
  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ATyr shares plunge on trial miss in inflammatory lung disease

    The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.

    By • Sept. 15, 2025
  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology

    Early academic research suggests various ways weight loss drugs could have an impact in cancer care.

    By Michael Gibney • Sept. 12, 2025
  • A BioNTech logo hangs on the side of an office building.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    BioNTech says dual-acting lung cancer drug helped shrink tumors

    The Bristol Myers-partnered bispecific antibody kept small cell lung cancer under control in participants enrolled in a Phase 2 trial.

    By • Sept. 8, 2025
  • A brain scan is seen on a computer screen in an empty medical laboratory.
    Image attribution tooltip
    Dragos Condrea via Getty Images
    Image attribution tooltip
    Brain drug revival

    A new class of sleep drugs draws Wall Street’s attention

    Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

    By • Sept. 8, 2025
  • Image attribution tooltip
    Jens Schlueter via Getty Images
    Image attribution tooltip
    Vaccines

    Pfizer, BioNTech showcase new data supporting COVID booster

    The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.

    By • Sept. 8, 2025
  • A medical Illustration showing lung cancer or bronchial carcinoma.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    New Summit data clouds approval pathway in lung cancer

    A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.

    By • Sept. 8, 2025
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Rapport shares double on better-than-expected seizure drug data

    One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset seizures.

    By Ned Pagliarulo • Sept. 8, 2025
  • Doctor works on HUD or graphic display in front of her
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Sponsored by Pfizer

    Harnessing the power of AI to detect ATTR-CM

    From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.

    Sept. 8, 2025
  • Woman about to stand on a weighing scale
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Sponsored by IQVIA Technologies

    How sponsors are staying ahead in the obesity trial landscape

    Aligning digital innovation with thoughtful design is accelerating progress.

    Sept. 8, 2025
  • A white sign bears the word Sanofi at a road entrance to an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sanofi’s touted eczema drug hits study goal, but data fall short of expectations

    Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug class once viewed as particularly promising.

    By Kristin Jensen • Sept. 4, 2025
  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Wave shares sink on new study results for RNA editing drug

    Updated findings from Wave’s pioneering trial continued to show its RNA editing therapy is working as intended, but wasn’t as effective in testing as investors had hoped.  

    By • Sept. 3, 2025
  • The exterior of Ionis Pharmaceuticals' headquarters in Carlsbad, California.
    Image attribution tooltip
    Courtesy of Ionis Pharmaceuticals
    Image attribution tooltip

    Ionis looks to expand use of lipid-lowering drug after trial hits goal

    Tryngolza, the first wholly owned drug Ionis has launched, helped people with high triglyceride levels that aren’t genetically driven.

    By • Sept. 2, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly says breast cancer drug extended survival in study

    Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.

    By • Aug. 27, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly to submit obesity pill after hitting goal in third late-stage trial

    In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

    By • Aug. 26, 2025
  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial

    Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn't appear as effective.

    By Ned Pagliarulo • Updated Aug. 26, 2025
  • An illustration of glucose-dependent insulinotropic peptide.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Viking shares sink as obesity pill misses expectations in key study

    The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Viking’s drug. 

    By • Aug. 19, 2025
  • A gloved hand holds a cluster of psilocybin mushrooms growing from a block of mycelium, illuminated by indoor lab lighting.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Reunion’s psychedelic drug headed to late-stage testing

    The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now setting up a larger experiment to hopefully secure approval in postpartum depression.

    By • Aug. 18, 2025
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vor says drug licensed from RemeGen succeeded in Sjögren’s study

    While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition.

    By Ned Pagliarulo • Aug. 13, 2025
  • A stylized illustration of the human urinary system with the bladder highlighted.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pfizer looks to expand ADC use after positive bladder cancer data

    Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.

    By • Aug. 12, 2025
  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    IO Biotech sees path forward for skin cancer vaccine despite study setback

    A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe it still could win U.S. approval.

    By • Aug. 11, 2025
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

    The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.

    By • Aug. 11, 2025